A Phase 1, Double Blind, Randomised, Placebo-Controlled, Multi-centre, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2693 in Patients With Non-alcoholic Steatohepatitis (NASH) With Fibrosis Stage 0-3 and Homozygous for the PNPLA3 148M Risk Allele
Latest Information Update: 30 Dec 2024
Price :
$35 *
At a glance
- Drugs ION 839 (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors AstraZeneca
- 16 Jan 2024 Status changed from active, no longer recruiting to completed.
- 11 Aug 2023 Planned End Date changed from 4 Mar 2024 to 18 Dec 2023.
- 11 Aug 2023 Planned primary completion date changed from 4 Mar 2024 to 18 Dec 2023.